Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Yaseen M. Arabi(World Health Organization), Katrina Orr(University of Auckland), Lise J Estcourt(NHS Blood and Transplant), Susan C. Morpeth, Lolowa Al Swaidan(King Saud bin Abdulaziz University for Health Sciences), Patrick R. Lawler(McGill University Health Centre), Ewan C. Goligher(University Health Network), Daniel F. McAuley(Queen's University Belfast), Alistair Nichol(University College Dublin), Christopher M. Horvat(University of Pittsburgh), Elizabeth Lorenzi(Berry & Associates (United States)), Anthony Gordon(University of Copenhagen), Marc J. M. Bonten(Utrecht University), Rachael Parke(University of Auckland), Paul Mouncey(Intensive Care National Audit & Research Centre), Richard Beasley(Medical Research Institute of New Zealand), Roger Lewis(University of California, Los Angeles), Alisa M. Higgins(Monash University), Farah Al Beidh(Imperial College London), Salim Malakouti(University of Pittsburgh), Djillali Annane(Hôpital Raymond-Poincaré), Michelle A. Detry(Berry & Associates (United States)), Bryan J. McVerry(University of Pittsburgh), Menno D. de Jong(National Institute for Public Health and the Environment), Thomas Hills(Auckland City Hospital), Andrew J. King(University of Pittsburgh), Anna McGlothlin(Berry & Associates (United States)), Charlotte Bradbury(University of Bristol), Frank M. Brunkhorst(Jena University Hospital), Lindsay R. Berry(Berry & Associates (United States)), Mark Fitzgerald(Berry & Associates (United States)), Timothy D. Girard(University of Pittsburgh), Stephanie K. Montgomery(University of Pittsburgh), Kelsey Linstrum(University of Pittsburgh), Adrian Buzgau(Monash University), Herman Goossens(Antwerp University Hospital), Eamon Duffy(Auckland City Hospital), Lennie Derde
Intensive Care Medicine
July 12, 2021
Cited by 100


Related Papers